BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the seco
How this was made
The 30-second read
Why it matters
The disclosed trial milestones provide fresh data points for investors, while the financials show higher losses but a strong cash position, influencing valuation models.
Market read
The filing introduces new clinical trial progress and financial metrics that can move BIOA's stock, with broader relevance to the aging‑biology biotech niche.
What to watch
Potential regulatory delays or trial setbacks not yet disclosed could affect future valuations.
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
BioAge advanced BGE-102 through enrollment completion in QUELL-CV and first-patient dosing in QUELL-DME, while ending the quarter with approximately $352.3 million in cash, cash equivalents, and marketable securities and estimated funding through 2029. Financial results reflected sharply higher BGE-102 clinical and manufacturing spending, lower collaboration revenue, and a wider net loss.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenueGAAP | $300K | – | $1.8 million decrease |
| Research and development expensesGAAP | $30.2M | – | $11.7 million increase |
| General and administrative expensesGAAP | $7.5M | – | $0.8 million increase |
| Total operating expensesGAAP | 37,709 | – | – |
| Loss from operationsGAAP | (37,411) | – | – |
| Interest expenseGAAP | — | – | – |
| Interest and other income (expense), netGAAP | 3,393 | – | – |
| Gain (loss) from changes in fair value of warrantsGAAP | 514 | – | – |
| Total other income (expense), netGAAP | 3,907 | – | – |
| Net lossGAAP | $33.5M | – | – |
| Net loss per share attributable to common stockholders, basic and dilutedGAAP | $0.73 | – | – |
| Weighted-average common shares outstanding, basic and dilutedGAAP | 45,911,481 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Collaboration revenueThe decrease was primarily due to a $1.7 million cumulative catch-up adjustment recorded in connection with a September 2026 amendment to the Novartis Agreement, which added $0.9 million of research funding and expanded the research activities to be performed. | $300K | – | $1.8 million decrease |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Fourth quarter of 2026, year-end 2026, second half of 2027, and through 2029 outlook
- NoteTopline data from QUELL-CV are anticipated in the fourth quarter of 2026.
- NoteThe Company intends to file its first IND for an APJ program by year-end 2026.
- NoteTopline results from QUELL-DME are anticipated in the second half of 2027.
- NoteBioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.
What drove it
- QUELL-CV completed enrollment of approximately 160 participants and topline data are anticipated in the fourth quarter of 2026.
- The first participant was dosed in QUELL-DME in September 2026; the approximately 180-participant trial has topline results anticipated in the second half of 2027.
- Research and development expense increased primarily because of a $13.2 million increase in BGE-102 direct costs related to QUELL-CV and QUELL-DME clinical trial costs and drug product manufacturing costs.
- Research and development expense was also driven by a $1.7 million increase in personnel-related expenses from increased headcount and higher stock-based compensation expense.
- The Deep Origin collaboration reached its first milestone in October 2026, with computationally identified hits validated in BioAge's laboratory.
Concerns
- Collaboration revenue declined due primarily to a $1.7 million cumulative catch-up adjustment associated with the September 2026 Novartis Agreement amendment.
- Net loss widened to $33.5 million from $20.2 million as research and development expenses increased to support BGE-102 clinical development and manufacturing.
- QUELL-DME topline results are not anticipated until the second half of 2027.
- The release identifies risks associated with clinical trials, unexpected concerns from additional data or analysis, regulatory approvals, and the ability to manage clinical activities for BGE-102 and APJ programs.
What to watch
- QUELL-CV topline data anticipated in the fourth quarter of 2026, including percent change from baseline in hsCRP over 12 weeks of dosing.
- The intended first IND filing for an APJ program by year-end 2026.
- QUELL-DME progress toward topline results anticipated in the second half of 2027, with change from baseline in best-corrected visual acuity at week 12 as the primary endpoint.
- The pace of BGE-102 clinical trial and drug product manufacturing costs.
- Progress of the Novartis, Lilly ExploR&D, and Deep Origin collaborations.
Balance sheet and cash flow
- Cash and cash equivalents were $52,666 as of September 30, 2026, compared to $188,888 as of December 31, 2025.
- Marketable securities, current were $230,971 as of September 30, 2026, compared to $92,210 as of December 31, 2025.
- Marketable securities were $68,680 as of September 30, 2026, compared to $4,032 as of December 31, 2025.
- Cash, cash equivalents, and marketable securities were approximately $352.3 million as of September 30, 2026.
- Current portion of term loan was — as of September 30, 2026, compared to 2,648 as of December 31, 2025.
- Total assets were $367,648 as of September 30, 2026, compared to $294,889 as of December 31, 2025.
- Total liabilities were 21,202 as of September 30, 2026, compared to 22,838 as of December 31, 2025.
- Total stockholders’ equity was 346,446 as of September 30, 2026, compared to 272,051 as of December 31, 2025.
Analysis
BioAge's third-quarter update was defined by clinical execution rather than commercial revenue. QUELL-CV completed enrollment of approximately 160 participants, with topline data anticipated in the fourth quarter of 2026. The company also dosed the first participant in QUELL-DME during September 2026. That approximately 180-participant study evaluates BGE-102 as monotherapy and with anti-VEGF therapy, with topline results anticipated in the second half of 2027. The APJ agonist program remains targeted for a first IND filing by year-end 2026.
Financial results show a marked increase in development spending. Research and development expenses rose to $30.2 million from $18.5 million, primarily reflecting a $13.2 million increase in BGE-102 direct costs for QUELL-CV and QUELL-DME clinical work and drug product manufacturing. A $1.7 million increase in personnel-related expenses also contributed. General and administrative expenses increased to $7.5 million from $6.7 million, led by higher stock-based compensation and consulting fees. Net loss widened to $33.5 million, or $0.73 per weighted-average common share outstanding, basic and diluted, from $20.2 million, or $0.56 per weighted-average common share outstanding, basic and diluted.
Collaboration revenue declined to $0.3 million from $2.1 million. The company attributed the $1.8 million decrease primarily to a $1.7 million cumulative catch-up adjustment related to a September 2026 amendment to the Novartis Agreement. The amendment added $0.9 million of research funding and expanded the research activities to be performed, increasing the total estimated effort required to satisfy the performance obligation. This revenue movement is therefore tied to accounting for the amended collaboration rather than a disclosed change in the underlying clinical pipeline.
Liquidity remains a central support for the development plan. BioAge reported approximately $352.3 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and estimates that these resources will fund operations and capital expenses through 2029. Cash and cash equivalents were $52,666, while current and noncurrent marketable securities were $230,971 and $68,680, respectively. The current portion of the term loan was reported as — at September 30, 2026, compared with 2,648 at December 31, 2025.
The next material operating event is the anticipated fourth-quarter 2026 QUELL-CV readout. Its primary endpoint is percent change from baseline in hsCRP over 12 weeks, and the trial is intended to characterize the BGE-102 dose-response relationship and support dose selection for further development. Longer term, investors will focus on the APJ IND timing, the progression of QUELL-DME, and whether the company can manage the higher clinical and manufacturing cost base while advancing its multiple early-stage programs.
Management, verbatim
BGE-102 has a potential best-in-class profile: in Phase 1, it suppressed IL-1β by up to 98% with once-daily dosing and was well tolerated.
Kristen Fortney, Ph.D., CEO and co-founder of BioAge
Our Phase 2 cardiovascular study, QUELL-CV, is fully enrolled, and we expect the results later this year to inform the optimal dose and show how BGE-102 could affect a range of metabolic and inflammatory markers.
Kristen Fortney, Ph.D., CEO and co-founder of BioAge
With a strong cash position, we are well positioned to advance BGE-102 and our apelin and other programs.
Kristen Fortney, Ph.D., CEO and co-founder of BioAge
Not in the filing
stated, not guessed- Total revenue separate from collaboration revenue
- Gross profit and gross margin
- Operating cash flow
- Free cash flow
- Capital expenditures
- Share repurchases
- Dividends
- Non-GAAP financial measures
- Financial revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Previous-release outlook for comparison
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BioAge Labs is a clinical‑stage biopharma focusing on cardiometabolic diseases via aging biology, filing its quarterly 8‑K with trial updates and financials.
Ticker impact
BioAge Labs reported Q3 2026 financial results and provided updates on its BGE-102 Phase 2 trials, including first patient dosed in QUELL-DME and enrollment completion for QUELL-CV.
potential modest upside as investors price in trial advancement and cash runway
First‑time disclosure of trial dosing and enrollment milestones is new material for a clinical‑stage biotech; markets typically react positively to forward‑looking pipeline news, though increased R&D spend tempers impact.
Market effects
Advances in BGE-102 may boost interest in NLRP3 inhibitors across biotech sector.
U.S. biotech investors may adjust exposure to aging‑related therapeutics.
Limited to investors tracking clinical‑stage biotech pipelines.
Counterpoint
Increased R&D spend and cash burn could outweigh trial progress, leading to short‑term pressure.
Key entities
- companyBioAge Labs, Inc.
NASDAQ‑listed biotech developing BGE-102 and APJ agonist programs.
- partnerNovartis
Collaboration partner providing research funding.
- partnerEli Lilly
Collaboration on therapeutic antibodies.
